Natalie Vokes

@IDEOlogyHealth All of these time points would be valid times to check as we incorporate new biomarkers into practice

IDEO Xchange: When is c‑MET IHC typically performed at your clinic?

@IDEOlogyHealth Good data from the cocoon trial supporting prophylaxis!

IDEO Xchange: When do you typically initiate dermatologic prophylaxis for patients starting 1L sub-q amivantimab + lazertinib in clinic?

@IDEOlogyHealth OS data supports combination, but have to consider patient-specific factors and goals

IDEO Xchange: Based upon recent data, how convinced are you that initiating combination therapy in 1L should be the SOC inEGFR+ mNSCLC?

Biomarker complexity is rapidly increasing, yet the cost and accessibility of the technologies needed to implement them are not always keeping pace In @JTOonline, our comprehensive study of the routinely-assessed TTF-1 expression in lung adenocarcinoma jto.org/article/S1556-… 1/7

Special mention to @LeiDeng3 and Bolun Liu for their analysis of NCDB dataset, and the teams of @BRicciutiMD, @DiFedericoMD, @alissajcooper and @AdamJSchoenfeld for their collaboration. Hope that such studies can pave the way for better treatment options in these rare tumors!

Delighted to share this multi-institutional collaboration dissecting outcomes in sarcomatoid lung cancer, a rare and hard to treat subtype. While chemotherapy may have limited efficacy, we found that many of these tumors are PDL1 high and responsive to immunotherapy.

Outcomes to ICIs and genomic features in PSC remain underexplored compared with other NSCLC subtypes. Hong et al. present the findings from their multicenter retrospective study on clinicogenomic features and #immunotherapy associations in PSC. bit.ly/3MDgrTX @NIvokes

New #JITC article: Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial bit.ly/47kd782 @StevenLin_MDPhD @liao_zhongxing @dave_qian @ca_chung @NIVokes @JiaWu_PhD @JoeChangMD @MDAndersonNews

🚨 Excited to share our 2 new studies published today in @TheLancetOncol — one offering deeper insight into refining #ICI for PD-L1–negative & 🧬#STK11-mutant #NSCLC, and the other exploring #ICI vs 💊#BRAF/MEKi in #BRAF V600E #NSCLC. @OncoAlert @IASLC #LCSM. /W✨@DiFedericoMD✨ These studies aren’t full answers — but we hope they help sharpen strategies and spark further progress in tailoring immunotherapy for NSCLCs historically seen as resistant. Heartfelt thanks to the co-authors, patients, collaborators & reviewers who made this possible. @marinagarassino @MarceloCorassa @peters_solange @pecci_federica1 @ACortelliniMD @dplanchard @RobertoFerrara_ @CoreyLangerMD @FawziAbuRous @mihaela_aldea @XinAnnWang @DanaFarber @DanaFarberNews @DrMarkAwad @NIVokes @StephenVLiu @NarjustFlorezMD @alessi_joao @DrJNaidoo @Alfdoc2

NSCLC MTAP-del BMS-986504 (MTA-coop PRMT5i) in pretreated pts: ORR 29% · DOR 10.5m · DCR 80% Active in EGFR/ALK/KRAS subgroups. Well tolerated, low heme tox. ➡️ Next step: MountainTAP-9 & 29 #LungCancer #Oncology #TargetedTherapy #wclc25 @IASLC @OncoAlert

Loving the poster vibes at #WCLC2025! 😎 Connecting with mentors & friends = best part. Always learning! 📚💡@drgandara @ChristineBestv1 @NIVokes

Great to see so much data coming out in this space, with many clinical trials now available or coming for patients with MTAP deletions including at @MDAndersonNews and other centers

Important paper put out by stellar MDA colleagues! Congrats to all co- authors. @LaurenByersMD @NIVokes John Heymach @MDAndersonNews

🌟 A remarkable oral session at #ASCO25 showcasing that the future of lung cancer care is bright! 👏 Hats off to the incredible chairs @BrunaPellini @NIVokes, all speakers and insightful discussants @LealTiciana @VanitaNoronha @MarceloCorassa , who brought both science of #LungCancer and practical wisdom to the stage. With that, I, @Jani_Chinmay @SylvesterCancer @HemOncMiami sign off from twitter take over for @VJOncology - it’s been a pleasure sharing live updates with you all!

Great to meet with our lung cancer experts at @MDAndersonNews and thanks for the consult! @lungoncdoc @NIVokes #ASCO2025

Best way to start #ASCO25 Sunday is with new NSCLC data! Come by Arie Crown at 8 for exciting abstracts and discussion, cochairing with @BrunaPellini #LCSM

Happening soon at #ASCO25!! Dr. @BrunaPellini (@MoffittNews) and Dr. @NIVokes (@MDAndersonNews) will be chairing the metastatic NSCLC session! Exciting data on the way! @ASCO

Come see us at #ASCO25 at the @MDAndersonNews Booth! @NIVokes @FSkoulidis #EndCancer

Great chat with @NIVokes and @JJSingleton1 about immunotherapy. What it is and what it’s like to receive it from the experts!

Confused about immunotherapy? Listen to @NIVokes and @JJSingleton1 getting into the nuts and bolts of how it works and how it feels to get it! Ep 09: What Immunotherapy Really Means for Patients | Cracking Cancer Po... youtu.be/2YFlww-N29M?si… via @YouTube